How Early Can Imaging Assess Response in End-Stage Prostate Cancer?

177Lu-PSMA SPECT at cycle three (week 12) of six cycles of PSMA-targeted treatment predicted progression-free survival for men with end-stage metastatic castration-resistant prostate cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/982909?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?